A Phase 2 interventional study of REGN5381 and Placebo in Uncontrolled Hypertension, sponsored by Regeneron Pharmaceuticals. Terminated at 3 sites in United Kingdom. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-23.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 223 studies in Hypertension with a site in United Kingdom — 35 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.
Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 138th largest by enrollment of the 172 interventional ones that give a count, is one of 13 that started in 2025, is one of 26 in phase 2, and was the 208th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →35 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:
CRISPR Therapeutics AG · Sites in United Kingdom, United States, Australia
Ages 18–75
King's College London · Sites in United Kingdom
Ages 10–25 · Healthy volunteers
Northumbria University · Sites in United Kingdom
Ages 18+
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18–40
Medtronic Vascular · Sites in United Kingdom, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 48 · Phase 4 20
First in 1997; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 125 across the 172 interventional studies, 200 across the 50 observational. Of the 156 that completed or were terminated, 52 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 223 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
11 of the studies in Hypertension with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07294794University of BirminghamPersonalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 223 studies in Hypertension with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on uncontrolled hypertension (high blood pressure despite being on one or more antihypertensive drugs).
The aim of the study is to see how effective the study drug is in reducing blood pressure. The study is designed as a 2-part study with participants initially enrolling in Part A. Part B of the study will commence and enroll the remaining study participants.
The study is looking at several other research questions, including:
As of October 15, 2025, this study has been terminated, and all future onsite visits have been canceled. However, participants have been asked to report safety information to the trial helpline until January 15, 2026.
Key Inclusion Criteria:
Key Exclusion Criteria
NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized as described in the protocol
Drug: REGN5381
Randomized as described in the protocol
Drug: REGN5381
Randomized as described in the protocol
Drug: Placebo
Administered per the protocol
Administered per the protocol
Unattended Automated Office-Based Blood Pressure (AOBP) Systolic Blood Pressure (SBP)
Time frame: At week 12
Unattended AOBP SBP in stage 3 Chronic Kidney Disease (CKD) participants
Time frame: At week 12
Unattended AOBP SBP in participants on ≥3 anti-hypertensive therapies
Time frame: At week 12
Time-weighted average AOBP SBP
Time frame: Through week 12
Time-weighted average AOBP Diastolic Blood Pressure (DBP)
Time frame: Through week 12
AOBP SBP
Time frame: From baseline to weeks 2, 4 and 8
AOBP DBP
Time frame: From baseline to weeks 2, 4, 8 and 12
Mean SBP by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)
Time frame: At week 12
Concentrations of REGN5381 in serum
Time frame: Through week 20
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to week 23
Severity of TEAEs
Time frame: Up to week 23
Occurrence of TEAEs leading to discontinuation of study drug
Time frame: Up to week 23
Occurrence of Anti-Drug Antibodies (ADAs) to REGN5381
Time frame: Through week 20
Titer of ADAs to REGN5381
Time frame: Through week 20
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Oct 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vixticibart